July 28, 2021
Oncolytic Virus Teserpaturev Approved in Japan for Malignant Glioma BookmarkGeorge Lundberg, MD
Oncolytic viruses may offer serious hope as a very new type of treatment for malignant glioma. As reported by OncLive, the oncolytic virus teserpaturev was recently approved in Japan after a phase 2 clinical trial.
August 15, 2020
ATIM-14. Results of Phase II Clinical Trial of Oncolytic Herpes Virus G47∆ in Patients with Glioblastoma BookmarkGeorge Lundberg, MD
Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes:
In a phase 2 clinical trial, glioblastoma patients were treated with a herpes virus that has been genetically engineered to kill cancer cells. The genetically engineered virus is injected directly into patients’ brain tumors. It is early and the numbers are small, but the trial produced amazing results compared to historical controls.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.